How can nanoparticles be used to overcome the challenges of glaucoma treatment?

References

• 1 Quigley AH, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol. 90, 262–267 (2006).
  Medline CASGoogle Scholar
• 2 Tan YF, Mundargi RC, Chen MHA et al. Layer-by-layer nanoparticles as an efficient siRNA delivery vehicle for SPARC silencing. Small 10(9), 1790–1798 (2014).
  Medline CASGoogle Scholar
• 3 Ciolino JB, Stefanescu CF, Ross AE et al. In vivo performance of a drug-eluting contact lens to treat glaucoma for a month. Biomaterials 35, 432–439 (2014).
  Medline CASGoogle Scholar
• 4 Chong RS, Su DH, Tsai A et al. Patient acceptance and attitude toward an alternative method of subconjunctival injection for the medical treatment of glaucoma. J. Glaucoma. 22(3), 190–194 (2013).
  MedlineGoogle Scholar
• 5 Jayaganesh NV, Darwitan A, Barathi VA et al. Sustained drug release in nanomedicine: a long-acting nanocarrier-based formulation for glaucoma. ACS Nano 8(1), 419–429 (2014).
  MedlineGoogle Scholar
• 6 Wong TT, Novack GD, Ho CL, Jayaganesh NV, Htoon HM, Venkatraman SS. Nanomedicine for glaucoma: sustained release latanoprost offers a new therapeutic option with substantial benefits over eye drops. Drug Deliv. Transl. Res. 4(4), 303–309 (2014).
  MedlineGoogle Scholar
• 7 Abrishami M, Ganavati SZ, Soroush D, Rouhbaksh M, jaafari MR, Malaekeh-Nikouei: Preparation, characterization and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (Avastin) for intravitreal administration. Retina 29, 699–703 (2009).
  MedlineGoogle Scholar
• 8 Honda M, Asai T, Oku N, Tanaka M, Ebihara N. Liposomes and nanotechnology in drug development: focus on ocular therapies. Int. J. Nanomedicine 8, 495–504 (2013).
  MedlineGoogle Scholar
• 9 pSivida Corp. www.psivida.com/products-iluvien.html
  Google Scholar